Business context and reporting period
This filing is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2016 (fiscal Q1 2017), not an Edesa Biotech filing. Stellar develops, manufactures and commercializes Keyhole Limpet Hemocyanin (KLH) for pharmaceutical, biotechnology and research markets. Financial amounts are U.S. dollars.
Key financial metrics
| Metric | Quarter ended Dec. 31, 2016 | Comparable 2015 quarter / prior balance-sheet date |
|---|---|---|
| Revenue | $141,856 | $488,160 |
| Gross profit on product sales and contract services, as presented | $63,291; 44.6% of revenue | $176,097; 36.1% of revenue |
| Operating loss | $1,414,476 | $1,307,354 |
| Net loss | $1,485,672 | $1,629,803 |
| Basic and diluted loss per share | $0.15 | $0.19 |
| Operating cash used | $1,365,034 | $1,174,545 |
| Cash and cash equivalents | $5,885,409 | $7,416,904 at Sept. 30, 2016 |
| Short-term investments | $3,993,598 | $3,988,794 at Sept. 30, 2016 |
| Working capital | $9,987,827 | $11,476,011 at Sept. 30, 2016 |
| Total assets / current liabilities | $11,467,053 / $602,123 | $12,937,804 / $623,644 at Sept. 30, 2016 |
Capital expenditures were $84,424 in cash. The balance sheet lists no borrowings or other debt; liabilities shown are accounts payable and accrued liabilities. The company reported no off-balance-sheet arrangements with a material effect.
Material changes versus the prior comparable period
- Revenue fell $346,304, or about 71%, mainly because product sales volumes declined; there was no contract-services revenue after the prior collaboration ended in December 2015.
- Total expenses declined about 13% to $1.56 million. Lower cost of sales and general and administrative expenses were partly offset by R&D rising $172,016 to $460,865, principally for manufacturing scale-up, process improvements and aquaculture work, including the Mexico feasibility assessment.
- Operating loss widened by $107,122, while net loss narrowed by $144,131. The net-loss improvement chiefly reflected the absence of the prior-year $211,956 noncash warrant-liability fair-value loss.
- Operating cash use increased by $190,489. Cash and cash equivalents declined $1.53 million during the quarter; there were no financing proceeds in the period, unlike the prior-year quarter.
Outlook, risks, contingencies and unusual items
- Management said working capital was sufficient for current initiatives, contractual obligations and anticipated R&D for at least 12 months at the current level. It expects continued losses and may seek equity, debt, grants, collaborations or licensing; no new financing commitment was secured, and availability on acceptable terms is not assured. No specific revenue or earnings guidance was provided.
- Revenue is exposed to fluctuations in customers’ clinical-development programs. Customer concentration increased: one customer accounted for 92% of current-quarter revenue, versus three customers accounting for 85% in the prior-year quarter. Europe represented 94% of current-quarter revenue.
- The company had approximately $253,000 of commitments to contract research organizations and consultants and an estimated $33,000 to contractors, expected to be fulfilled within 12 months; future minimum lease payments totaled $547,000.
- A 30% interest in a French vaccine joint venture may require further pro-rata financing. The venture could be dissolved if specified milestones are not achieved by December 2017, subject to the agreement’s alternatives.
- A KLH-related license includes up to $6.02 million in contingent development and financing milestones and $57.025 million in sales-target milestones, plus royalties if applicable. No royalties had been incurred to date; most milestone payments are contingent.
- In January 2017, the company formed a Mexican subsidiary to support evaluation of a potential second aquaculture facility. This is a subsequent event, not a facility or production capacity already established.
- Foreign-exchange loss was $77,390, including a $77,233 adverse exchange-rate effect on cash. Management reported no material changes to previously disclosed risk factors or market risks and no material legal proceedings outside the ordinary course.
- Management concluded disclosure controls were effective as of December 31, 2016; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm issuer and period: the supplied filing identifies Stellar Biotechnologies, Inc. and the quarter ended December 31, 2016, despite request metadata naming Edesa Biotech and 2017 Q1.
- Track customer concentration, sales volumes and the development progress of third-party products using KLH, which drive variable product demand.
- Assess cash runway against the reported quarterly operating cash use, planned manufacturing and Mexico-related spending, and management’s 12-month sufficiency statement.
- Review the joint venture’s December 2017 milestone conditions, potential funding needs, and the contingent license payments and royalties.
- Check whether future financing is raised and whether the planned manufacturing scale-up and potential second aquaculture site achieve commercial and operational milestones.